A research team led by investigators at Virginia Commonwealth University found evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.
As people continue to live longer and the survival rate of cancer diagnoses increases, researchers from VCU Massey Comprehensive Cancer Center decided to lead a multi-decade analysis studying the rates of subsequent primary cancers, which are new cancers unrelated to the original diagnosis.
